Improving prospects for targeting RAS

Journal of Clinical Oncology

Volumn 33, Issue 31, 2015, Pages 3650-3659

  Singh, Harshabad ^a,b   Longo, Dan L ^c   Chabner, Bruce A ^a  

^a MASSACHUSETTS GENERAL HOSPITAL CANCER CENTER   (United States)

^b DANA FARBER CANCER INSTITUTE   (United States)

^c BRIGHAM AND WOMEN S HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

K RAS PROTEIN; RAS PROTEIN; ANTINEOPLASTIC AGENT; KRAS PROTEIN, HUMAN; KRAS4B PROTEIN, MOUSE; PROTEIN P21;

ARTICLE; CANCER CELL; CELL DIFFERENTIATION; CELL PROLIFERATION; GENE MUTATION; HUMAN; LYMPHOCYTE PROLIFERATION; MOLECULARLY TARGETED THERAPY; NONHUMAN; PHASE 2 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; PROTEIN DOMAIN; PROTEIN FUNCTION; PROTEIN LOCALIZATION; PROTEIN PROCESSING; PROTEIN STRUCTURE; PROTEIN TARGETING; PROTEIN TRANSPORT; RANDOMIZED CONTROLLED TRIAL (TOPIC); SIGNAL TRANSDUCTION; ANIMAL; ANTAGONISTS AND INHIBITORS; CANCER TRANSPLANTATION; CLINICAL TRIAL (TOPIC); GENETICS; METABOLISM; MOUSE; MUTATION; NEOPLASMS; ONCOGENE RAS;

ANIMALS; ANTINEOPLASTIC AGENTS; CLINICAL TRIALS AS TOPIC; GENES, RAS; HUMANS; MICE; MUTATION; NEOPLASM TRANSPLANTATION; NEOPLASMS; PROTO-ONCOGENE PROTEINS P21(RAS); RAS PROTEINS; SIGNAL TRANSDUCTION;

EID: 84947268351     PISSN: 0732183X     EISSN: 15277755     Source Type: Journal    
DOI: 10.1200/JCO.2015.62.1052     Document Type: Article

References (102)

1. Barbacid M: Ras genes. Annu Rev Biochem 56:779-827, 1987
2. Stephen AG, Esposito D, Bagni RK, et al: Dragging ras back in the ring. Cancer Cell 25:272-281, 2014
3. Sorich MJ, Wiese MD, Rowland A, et al: Extended RAS mutations and anti-EGFR monoclonal antibody survival benefit in metastatic colorectal cancer: A meta-analysis of randomized, controlled trials. Ann Oncol 26:13-21, 2015
4. Van Cutsem E, Köhne CH, Hitre E, et al: Cetuximab and chemotherapy as initial treatment for metastatic colorectal cancer. N Engl J Med 360:1408-1417, 2009
5. National Cancer Institute: The RAS Initiative: Development of the RAS Initiative at the Frederick National Laboratory for Cancer Research (FNLCR). http://www.cancer.gov/researchandfunding/priorities/ras
6. Thompson H: US National Cancer Institute's new Ras project targets an old foe. Nat Med 19:949-950, 2013
7. Cox AD, Fesik SW, Kimmelman AC, et al: Drugging the undruggable RAS: Mission possible? Nat Rev Drug Discov 13:828-851, 2014
8. Downward J: RAS synthetic lethal screens revisited: Still seeking the elusive prize? Clin Cancer Res 21:1802-1809, 2015
9. McCormick F: KRAS as a therapeutic target. Clin Cancer Res 21:1797-1801, 2015
10. Kimmelman AC: Metabolic dependencies in RAS-driven cancers. Clin Cancer Res 21:1828-1834, 2015
11. Marcus K, Mattos C: Direct attack on RAS: Intramolecular communication and mutation-specific effects. Clin Cancer Res 21:1810-1818, 2015
12. Cox AD, Der CJ, Philips MR: Targeting RAS membrane association: Back to the future for anti-RAS drug discovery? Clin Cancer Res 21:1819-1827, 2015
13. Ryan DP, Hong TS, Bardeesy N: Pancreatic adenocarcinoma. N Engl J Med 371:1039-1049, 2014
14. Forbes SA, Beare D, Gunasekaran P, et al: COSMIC: Exploring the world's knowledge of somatic mutations in human cancer. Nucleic Acids Res 43:D805-D811, 2015
15. Wellcome Trust Sanger Institute: COSMIC: Catalogue of Somatic Mutations in Cancer. http://cancer.sanger.ac.uk/cancergenome/projects/cosmic/
16. Ascierto PA, Schadendorf D, Berking C, et al: MEK162 for patients with advanced melanoma harbouring NRAS or Val600 BRAF mutations: A non-randomised, open-label phase 2 study. Lancet Oncol 14:249-256, 2013
17. Tolcher AW, Khan K, Ong M, et al: Antitumor activity in RAS-driven tumors by blocking AKT and MEK. Clin Cancer Res 21:739-748, 2015
18. Vetter IR, Wittinghofer A: The guanine nucleotide-binding switch in three dimensions. Science 294:1299-1304, 2001
19. Bos JL, Rehmann H, Wittinghofer A: GEFs and GAPs: Critical elements in the control of small G proteins. Cell 129:865-877, 2007
20. Krengel U, Schlichting I, Scherer A, et al: Three-dimensional structures of H-ras p21 mutants: Molecular basis for their inability to function as signal switch molecules. Cell 62:539-548, 1990
21. Scheffzek K, Ahmadian MR, Kabsch W, et al: The Ras-RasGAP complex: Structural basis for GTPase activation and its loss in oncogenic Ras mutants. Science 277:333-338, 1997
22. Rehmann H, Bos JL: Signal transduction: Thumbs up for inactivation. Nature 429:138-139, 2004
23. Spiegel J, Cromm PM, Zimmermann G, et al: Small-molecule modulation of Ras signaling. Nat Chem Biol 10:613-622, 2014
24. Ostrem JM, Peters U, Sos ML, et al: K-Ras(G12C) inhibitors allosterically control GTP affinity and effector interactions. Nature 503:548-551, 2013
25. Erlanson DA, Wells JA, Braisted AC: Tethering: Fragment-based drug discovery. Annu Rev Biophys Biomol Struct 33:199-223, 2004
26. Lim SM, Westover KD, Ficarro SB, et al: Therapeutic targeting of oncogenic K-Ras by a covalent catalytic site inhibitor. Angew Chem Int Ed Engl 53:199-204, 2014
27. Hunter JC, Gurbani D, Ficarro SB, et al: In situ selectivity profiling and crystal structure of SML-8-73-1, an active site inhibitor of oncogenic K-Ras G12C. Proc Natl Acad Sci U S A 111:8895-8900, 2014
28. Fu HW, Casey PJ: Enzymology and biology of CaaX protein prenylation. Recent Prog Horm Res 54:315-342, 1999
29. Hancock JF, Paterson H, Marshall CJ: A polybasic domain or palmitoylation is required in addition to the CAAX motif to localize p21ras to the plasma membrane. Cell 63:133-139, 1990
30. Hancock JF, Cadwallader K, Paterson H, et al: A CAAX or a CAAL motif and a second signal are sufficient for plasma membrane targeting of ras proteins. EMBO J 10:4033-4039, 1991
31. Barrington RE, Subler MA, Rands E, et al: A farnesyltransferase inhibitor induces tumor regression in transgenic mice harboring multiple oncogenic mutations by mediating alterations in both cell cycle control and apoptosis. Mol Cell Biol 18:85-92, 1998
32. Kohl NE, Omer CA, Conner MW, et al: Inhibition of farnesyltransferase induces regression of mammary and salivary carcinomas in ras transgenic mice. Nat Med 1:792-797, 1995
33. Adjei AA, Mauer A, Bruzek L, et al: Phase II study of the farnesyl transferase inhibitor R115777 in patients with advanced non-small-cell lung cancer. J Clin Oncol 21:1760-1766, 2003
34. Van Cutsem E, van de Velde H, Karasek P, et al: Phase III trial of gemcitabine plus tipifarnib compared with gemcitabine plus placebo in advanced pancreatic cancer. J Clin Oncol 22:1430-1438, 2004
35. Macdonald JS, McCoy S, Whitehead RP, et al: A phase II study of farnesyl transferase inhibitor R115777 in pancreatic cancer: A Southwest Oncology Group (SWOG 9924) study. Invest New Drugs 23:485-487, 2005
36. Gajewski TF, Salama AK, Niedzwiecki D, et al: Phase II study of the farnesyltransferase inhibitor R115777 in advanced melanoma (CALGB 500104). J Transl Med 10:246, 2012
37. Fiordalisi JJ, Johnson RL 2nd, Weinbaum CA, et al: High affinity for farnesyltransferase and alternative prenylation contribute individually to K-Ras4B resistance to farnesyltransferase inhibitors J Biol Chem 278:41718-41727, 2003
38. Whyte DB, Kirschmeier P, Hockenberry TN, et al: K- and N-Ras are geranylgeranylated in cells treated with farnesyl protein transferase inhibitors J Biol Chem 272:14459-14464, 1997
39. Liu M, Sjogren AK, Karlsson C, et al: Targeting the protein prenyltransferases efficiently reduces tumor development in mice with K-RAS-nduced lung cancer. Proc Natl Acad Sci U S A 107:6471-6476, 2010
40. deSolms SJ, Ciccarone TM, MacTough SC, et al: Dual protein farnesyltransferase-geranylgeranyltransferase-I inhibitors as potential cancer chemotherapeutic agents. J Med Chem 46 2973-2984, 2003
41. Lobell RB, Omer CA, Abrams MT, et al Evaluation of farnesyl: protein transferase and geranylgeranyl: protein transferase inhibitor combinations in preclinical models. Cancer Res 61:8758-8768, 2001
42. Haklai R, Weisz MG, Elad G, et al: Dislodgment and accelerated degradation of Ras. Biochemistry 37:1306-1314, 1998
43. Elad G, Paz A, Haklai R, et al: Targeting of K-Ras 4B by S-trans, trans-farnesyl thiosalicylic acid. Biochim Biophys Acta 1452:228-242, 1999
44. Beiner ME, Niv H, Haklai R, et al: Ras antagonist inhibits growth and chemosensitizes human epithelial ovarian cancer cells. Int J Gynecol Cancer 16:200-206, 2006
45. Haklai R, Elad-Sfadia G, Egozi Y, et al: Orally administered FTS (salirasib) inhibits human pancreatic tumor growth in nude mice. Cancer Chemother Pharmacol 61:89-96, 2008
46. Weisz B, Giehl K, Gana-Weisz M, et al: A new functional Ras antagonist inhibits human pancreatic tumor growth in nude mice. Oncogene 18 2579-2588, 1999
47. Halaschek-Wiener J, Wacheck V, Schlagbauer-Wadl H, et al: A novel Ras antagonist regulates both oncogenic Ras and the tumor suppressor p53 in colon cancer cells. Mol Med 6:693-704, 2000
48. Riely GJ, Johnson ML, Medina C, et al: A phase II trial of Salirasib in patients with lung adenocarcinomas with KRAS mutations. J Thorac Oncol 6:1435-1437, 2011
49. Laheru D, Shah P, Rajeshkumar NV, et al Integrated preclinical and clinical development of S-trans, trans-Farnesylthiosalicylic Acid (FTS, Salirasib) in pancreatic cancer. Invest New Drugs 30: 2391-2399, 2012
50. Philips MR: Ras hitchhikes on PDE6& Nat Cell Biol 14:128-129, 2012
51. Chandra A, Grecco HE, Pisupati V, et al: The GDI-like solubilizing factor PDEδ sustains the spatial organization and signalling of Ras family proteins. Nat Cell Biol 14:148-158, 2012
52. Zimmermann G, Papke B, Ismail S, et al Small molecule inhibition of the KRAS-PDES interaction impairs oncogenic KRAS signalling. Nature 497 638-642, 2013
53. Ihle NT, Byers LA, Kim ES, et al: Effect of KRAS oncogene substitutions on protein behavior: mplications for signaling and clinical outcome. J Natl Cancer Inst 104:228-239, 2012
54. Alagesan B, Contino G, Guimaraes AR, et al Combined MEK and PI3K inhibition in a mouse model of pancreatic cancer. Clin Cancer Res 21:396-404, 2015
55. Ihle NT, Lemos R Jr, Wipf P, et al: Mutations in the phosphatidylinositol-3-kinase pathway predict for antitumor activity of the inhibitor PX-866 whereas oncogenic Ras is a dominant predictor for resistance. Cancer Res 69:143-150, 2009
56. Engelman JA, Chen L, Tan X, et al: Effective use of PI3K and MEK inhibitors to treat mutant Kras G12D and PIK3CA H1047R murine lung cancers. Nat Med 14:1351-1356, 2008
57. Dan S, Okamura M, Seki M, et al: Correlating phosphatidylinositol 3-kinase inhibitor efficacy with signaling pathway status: In silico and biological evaluations. Cancer Res 70:4982-4994, 2010
58. Garnett MJ, Edelman EJ, Heidorn SJ, et al: Systematic identification of genomic markers of drug sensitivity in cancer cells. Nature 483:570-575, 2012
59. Infante JR, Fecher LA, Nallapareddy S, et al: Safety and efficacy results from the first-in-human study of the oral MEK 1/2 inhibitor GSK1120212. J Clin Oncol 28:204s, 2010 (suppl; abstr 2503)
60. Bodoky G, Timcheva C, Spigel DR, et al: A phase II open-label randomized study to assess the efficacy and safety of selumetinib (AZD6244 [ARRY-142886]) versus capecitabine in patients with advanced or metastatic pancreatic cancer who have failed first-line gemcitabine therapy. Invest New Drugs 30:1216-1223, 2012
61. Bennouna J, Lang I, Valladares-Ayerbes M, et al: A phase II, open-label, randomised study to assess the efficacy and safety of the MEK1/2 inhibitor AZD6244 (ARRY-142886) versus capecitabine monotherapy in patients with colorectal cancer who have failed one or two prior chemotherapeutic regimens. Invest New Drugs 29:1021-1028, 2011
62. Sos ML, Fischer S, Ullrich R, et al: Identifying genotype-dependent efficacy of single and combined PI3K- and MAPK-pathway inhibition in cancer. Proc Natl Acad Sci U S A 106:18351-18356, 2009
63. Jänne PA, Shaw AT, Pereira JR, et al: Selumetinib plus docetaxel for KRAS-mutant advanced non-small-cell lung cancer: A randomised, multicentre, placebo-controlled, phase 2 study. Lancet Oncol 14:38-47, 2013
64. Ebi H, Faber AC, Engelman JA, et al: Not just gRASping at flaws: Finding vulnerabilities to develop novel therapies for treating KRAS mutant cancers. Cancer Sci 105:499-505, 2014
65. Shapiro G, LoRusso P, Kwak EL, et al: Clinical combination of the MEK inhibitor GDC-0973 and the PI3K inhibitor GDC-0941: A first-in-human phase Ib study testing daily and intermittent dosing schedules in patients with advanced solid tumors. J Clin Oncol 29:195s, 2011 (suppl; abstr 3005∧)
66. Speranza G, Kinders RJ, Khin S, et al: Pharmacodynamic biomarker-driven trial of MK-2206, an AKT inhibitor, with AZD6244 (selumetinib), a MEK inhibitor, in patients with advanced colorectal carcinoma (CRC). J Clin Oncol 30:210s, 2012 (suppl; abstr 3529)
67. Bedard P, Tabernero J, Kurzrock R, et al: A phase lb, open-label, multicenter, dose-escalation study of the oral pan-PI3K inhibitor BKM120 in combination with the oral MEK1/2 inhibitor GSK1120212 in patients (pts) with selected advanced solid tumors. J Clin Oncol 30:173s, 2012 (suppl; abstr 3003)
68. Tolcher AW, Bendell JC, Papadopoulos KP, et al: A phase IB trial of the oral MEK inhibitor trametinib (GSK1120212) in combination with everolimus in patients with advanced solid tumors. Ann Oncol 26:58-64, 2015
69. Neel NF, Martin TD, Stratford JK, et al: The RalGEF-Ral effector signaling network: The road less traveled for anti-Ras drug discovery. Genes Cancer 2:275-287, 2011
70. Ferro E, Trabalzini L: RalGDS family members couple Ras to Ral signalling and that's not all. Cell Signal 22:1804-1810, 2010
71. Lim KH, O'Hayer K, Adam SJ, et al: Divergent roles for RalA and RalB in malignant growth of human pancreatic carcinoma cells. Curr Biol 16: 2385-2394, 2006
72. Yan C, Liu D, Li L, et al: Discovery and characterization of small molecules that target the GTPase Ral. Nature 515:443-447, 2014
73. McLornan DP, List A, Mufti GJ: Applying synthetic lethality for the selective targeting of cancer. N Engl J Med 371:1725-1735, 2014
74. Corcoran RB, Cheng KA, Hata AN, et al: Synthetic lethal interaction of combined BCL-XL and MEK inhibition promotes tumor regressions in KRAS mutant cancer models. Cancer Cell 23:121-128, 2013
75. Barbie DA, Tamayo P, Boehm JS, et al: Systematic RNA interference reveals that oncogenic KRAS-driven cancers require TBK1. Nature 462:108-112, 2009
76. Scholl C, Fröhling S, Dunn IF, et al: Synthetic lethal interaction between oncogenic KRAS dependency and STK33 suppression in human cancer cells. Cell 137:821-834, 2009
77. Kumar MS, Hancock DC, Molina-Arcas M, et al: The GATA2 transcriptional network is requisite for RAS oncogene-driven non-small cell lung cancer. Cell 149:642-655, 2012
78. Luo J, Emanuele MJ, Li D, et al: A genome-wide RNAi screen identifies multiple synthetic lethal interactions with the Ras oncogene. Cell 137:835-848, 2009
79. Meylan E, Dooley AL, Feldser DM, et al: Requirement for NF-kappaB signalling in a mouse model of lung adenocarcinoma. Nature 462:104-107, 2009
80. Puyol M, Martín A, Dubus P, et al: A synthetic lethal interaction between K-Ras oncogenes and Cdk4 unveils a therapeutic strategy for non-small cell lung carcinoma. Cancer Cell 18:63-73, 2010
81. Zhu Z, Aref AR, Cohoon TJ, et al: Inhibition of KRAS-driven tumorigenicity by interruption of an autocrine cytokine circuit. Cancer Discov 4:452-465, 2014
82. Kwong LN, Costello JC, Liu H, et al: Oncogenic NRAS signaling differentially regulates survival and proliferation in melanoma. Nat Med 18:1503-1510, 2012
83. Finn RS, Crown JP, Lang I, et al: The cyclin-dependent kinase 4/6 inhibitor palbociclib in combination with letrozole versus letrozole alone as first-line treatment of oestrogen receptor-positive, HER2-negative, advanced breast cancer (PALOMA-1/TRIO-18): A randomised phase 2 study. Lancet Oncol 16:25-35, 2015
84. Wolpin BM, Rubinson DA, Wang X, et al: Phase II and pharmacodynamic study of autophagy inhibition using hydroxychloroquine in patients with metastatic pancreatic adenocarcinoma. Oncologist 19:637-638, 2014
85. Weiss S, Bogen B: MHC class II-restricted presentation of intracellular antigen. Cell 64:767-776, 1991
86. Jung S, Schluesener HJ: Human T lymphocytes recognize a peptide of single point-mutated, oncogenic ras proteins. J Exp Med 173:273-276, 1991
87. Fenton RG, Taub DD, Kwak LW, et al: Cytotoxic T-cell response and in vivo protection against tumor cells harboring activated ras proto-oncogenes. J Natl Cancer Inst 85:1294-1302, 1993
88. Tsang KY, Nieroda CA, De Filippi R, et al Induction of human cytotoxic T cell lines directed against point-mutated p21 ras-derived synthetic peptides. Vaccine Res 3:183-194, 1994
89. Gjertsen MK, Bakka A, Breivik J, et al: Vaccination with mutant ras peptides and induction of T-cell responsiveness in pancreatic carcinoma patients carrying the corresponding RAS mutation. Lancet 346:1399-1400, 1995
90. Fossum B, Gedde-Dahl T 3rd, Breivik J, et al p21-ras-peptide-specific T-cell responses in a patient with colorectal cancer: CD4+ and CD8+ T cells recognize a peptide corresponding to a common mutation (13Gly->Asp). Int J Cancer 56:40-45, 1994
91. Qin H, Chen W, Takahashi M, et al: CD4+ T-cell immunity to mutated ras protein in pancreatic and colon cancer patients. Cancer Res 55:2984-2987, 1995
92. Gedde-Dahl T 3rd, Nilsen E, Thorsby E, et al Growth inhibition of a colonic adenocarcinoma cell line (HT29) by T cells specific for mutant p21 ras. Cancer Immunol Immunother 38:127-134, 1994
93. Carbone DP, Ciernik IF, Kelley MJ, et al: Immunization with mutant p53- and K-ras-derived peptides in cancer patients: Immune response and clinical outcome. J Clin Oncol 23:5099-5107, 2005
94. Gjertsen MK, Bakka A, Breivik J, et al: Ex vivo ras peptide vaccination in patients with advanced pancreatic cancer: Results: of a phase I/II study. Int J Cancer 65:450-453, 1996
95. Gjertsen MK, Buanes T, Rosseland AR, et al: Intradermal ras peptide vaccination with granulocyte-macrophage colony-stimulating factor as adjuvant: Clinical and immunological responses in patients with pancreatic adenocarcinoma. Int J Cancer 92:441-450, 2001
96. Hunger RE, Brand CU, Streit M, et al: Successful induction of immune responses against mutant ras in melanoma patients using intradermal injection of peptides and GM-CSF as adjuvant. Exp Dermatol 10:161-167, 2001
97. Meyer RG, Korn S, Micke P, et al: An open-label, prospective phase I/II study evaluating the immunogenicity and safety of a ras peptide vaccine plus GM-CSF in patients with non-small cell lung cancer. Lung Cancer 58:88-94, 2007
98. Rahma OE, Hamilton JM, Wojtowicz M, et al: The immunological and clinical effects of mutated ras peptide vaccine in combination with IL-2, GM-CSF, or both in patients with solid tumors. J Transl Med 12:55, 2014
99. Biragyn A, Longo DL: Neoplastic "Black Ops": Cancer's subversive tactics in overcoming host defenses. Semin Cancer Biol 22:50-59, 2012
100. Toubaji A, Achtar M, Provenzano M, et al: Pilot study of mutant ras peptide-based vaccine as an adjuvant treatment in pancreatic and colorectal cancers. Cancer Immunol Immunother 57:1413-1420, 2008
101. Weng TY, Yen MC, Huang CT, et al: DNA vaccine elicits an efficient antitumor response by targeting the mutant Kras in a transgenic mouse lung cancer model. Gene Ther 21:888-896, 2014
102. Snyder A, Makarov V, Merghoub T, et al: Genetic basis for clinical response to CTLA-4 blockade in melanoma. N Engl J Med 371:2189-2199, 2014